CNS Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
CNS Pharmaceuticals, Inc. (CNSP) reported Increase (Decrease) in Prepaid Expense and Other Assets of $647.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $353.21K, a 79.03% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $293.79K.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$961.82K, a 260.87% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$401.98K.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$302.80K, a 604.90% decline from fiscal 2024.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $59.97K.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$2.38M.
- CNS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$860.45K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $353.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $647.00K 10-Q · filed 2026-08-12 | -$314.82K derived: sum of 3 quarters · filed 2026-08-12 | -$716.80K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $293.79K 10-Q · filed 2026-05-14 | -$668.03K derived: sum of 2 quarters · filed 2026-05-14 | -$1.07M derived: sum of 3 quarters · filed 2026-05-14 | $614.15K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$961.82K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.36M derived: sum of 2 quarters · filed 2026-03-31 | $320.36K derived: sum of 3 quarters · filed 2026-08-12 | -$302.80K 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$401.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.28M derived: sum of 2 quarters · filed 2026-08-12 | $659.02K 10-Q · filed 2025-11-14 | $1.26M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.06M 10-Q · filed 2026-08-12 | $1.06M 10-Q · filed 2025-08-14 | $1.66M derived: sum of 3 quarters · filed 2026-08-12 | $1.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$623.16K 10-Q · filed 2026-05-14 | -$25.27K derived: sum of 2 quarters · filed 2026-05-14 | -$576.26K derived: sum of 3 quarters · filed 2026-05-14 | -$460.20K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $597.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $46.91K derived: sum of 2 quarters · filed 2026-03-31 | $162.97K derived: sum of 3 quarters · filed 2026-03-31 | $59.97K 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$550.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$434.93K derived: sum of 2 quarters · filed 2025-11-14 | -$537.92K 10-Q · filed 2025-11-14 | -$1.34M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $116.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $13.07K 10-Q · filed 2025-08-14 | -$787.19K derived: sum of 3 quarters · filed 2025-08-14 | -$1.54M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$102.99K 10-Q · filed 2025-05-15 | -$903.25K derived: sum of 2 quarters · filed 2025-05-15 | -$1.66M derived: sum of 3 quarters · filed 2025-05-15 | -$1.79M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$800.26K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.55M derived: sum of 2 quarters · filed 2025-03-31 | -$1.69M derived: sum of 3 quarters · filed 2025-03-31 | -$2.38M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$753.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$884.79K derived: sum of 2 quarters · filed 2024-11-14 | -$1.58M 10-Q · filed 2024-11-14 | -$1.30M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$130.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$823.07K 10-Q · filed 2024-08-14 | -$548.70K derived: sum of 3 quarters · filed 2024-08-14 | -$1.42M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$692.22K 10-Q · filed 2024-05-15 | -$417.85K derived: sum of 2 quarters · filed 2024-05-15 | -$1.29M derived: sum of 3 quarters · filed 2024-05-15 | -$1.23M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $274.37K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$601.15K derived: sum of 2 quarters · filed 2024-04-01 | -$542.33K derived: sum of 3 quarters · filed 2024-04-01 | -$860.45K 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$875.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$816.70K derived: sum of 2 quarters · filed 2023-11-14 | -$1.13M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $58.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$259.30K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$318.12K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |